-1.63%
-20.19%
-39.57%
9.59%
-2.53%
-61.19%
-69.91%
AI Spotlight on PRQR
Company Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.The company also engages in the developing of Axiomer RNA base-editing platform technology.
It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Market Data
| Last Price | 2.12 |
| Change Percentage | -1.63% |
| Open | 2.14 |
| Previous Close | 2.15 |
| Market Cap ( Millions) | 218 |
| Volume | 260607 |
| Year High | 4.62 |
| Year Low | 1.61 |
| M A 50 | 2.92 |
| M A 200 | 2.34 |
Financial Ratios
| FCF Yield | -17.46% |
| Dividend Yield | 0.00% |
| ROE | -71.11% |
| Debt / Equity | 69.64% |
| Net Debt / EBIDTA | 268.18% |
| Price To Book | 6.67 |
| Price Earnings Ratio | -6.99 |
| Price To FCF | -5.73 |
| Price To sales | 11.8 |
| EV / EBITDA | -5.16 |
News
- Dec -10 - ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
- Oct -25 - ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
- Oct -23 - ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
- Oct -22 - ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
- Oct -07 - ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
- Oct -02 - Best Momentum Stocks to Buy for October 2nd
- Sep -10 - ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
- May -11 - ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
- May -09 - ProQR Announces First Quarter 2024 Operating and Financial Results
- Apr -23 - ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
- Apr -22 - ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
- Apr -19 - ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
- Mar -13 - ProQR Announces Year End 2023 Operating and Financial Results
- Jan -19 - ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- Jan -05 - ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
- Dec -28 - Is ProQR (PRQR) Stock a Solid Choice Right Now?
- Dec -08 - ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
- Nov -07 - ProQR Announces Third Quarter 2023 Operating and Financial Results
- Nov -06 - ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
- Sep -28 - ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> RNA Based Therapeutics
Expected Growth : 11.43 %
What the company do ?
ProQR Therapeutics N.V.'s RNA-based therapeutics use RNA molecules to treat genetic diseases, restoring normal gene function by correcting or modifying RNA processing.
Why we expect these perspectives ?
ProQR Therapeutics N.V.'s RNA-based therapeutics growth is driven by increasing adoption in rare genetic diseases, advancements in RNA editing technologies, and a strong pipeline of candidates. The company's focus on unmet medical needs, strategic partnerships, and expanding research collaborations also contribute to its 11.43% growth.
Proqr Therapeutics N.V. Products
| Product Range | What is it ? |
|---|---|
| Sepofarsen | An RNA-based oligonucleotide in development for the treatment of Leber Congenital Amaurosis 10 (LCA10), a severe inherited retinal disease. |
| QR-421a | An RNA-based oligonucleotide in development for the treatment of Usher syndrome type 2, a genetic disorder that causes hearing loss and vision loss. |
| QR-1123 | An RNA-based oligonucleotide in development for the treatment of Autosomal Dominant Retinitis Pigmentosa (adRP), a genetic disorder that causes vision loss. |
| QR-313 | An RNA-based oligonucleotide in development for the treatment of Fuchs Endothelial Corneal Dystrophy, a genetic disorder that causes vision loss. |
ProQR Therapeutics N.V.'s Porter Forces
Threat Of Substitutes
ProQR Therapeutics N.V. is a biotech company that focuses on developing RNA-based therapies for severe genetic diseases. The threat of substitutes is medium because while there are other companies working on similar treatments, ProQR's RNA-based approach is unique and has shown promising results.
Bargaining Power Of Customers
ProQR Therapeutics N.V. is a biotech company that focuses on developing RNA-based therapies for severe genetic diseases. The bargaining power of customers is low because the company is still in the development stage and has not yet commercialized any products, giving customers limited bargaining power.
Bargaining Power Of Suppliers
ProQR Therapeutics N.V. relies on suppliers for raw materials and services necessary for its RNA-based therapies. The bargaining power of suppliers is medium because while there are some specialized suppliers, ProQR has some flexibility in choosing its suppliers.
Threat Of New Entrants
The biotech industry is highly competitive, and new entrants can easily disrupt the market. The threat of new entrants is high because ProQR Therapeutics N.V. operates in a highly competitive market with many established players and new entrants.
Intensity Of Rivalry
The biotech industry is highly competitive, and ProQR Therapeutics N.V. operates in a crowded market with many established players. The intensity of rivalry is high because companies are constantly competing for funding, talent, and market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 12.49% |
| Debt Cost | 5.42% |
| Equity Weight | 87.51% |
| Equity Cost | 5.42% |
| WACC | 5.42% |
| Leverage | 14.27% |
ProQR Therapeutics N.V. : Quality Control
ProQR Therapeutics N.V. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHM.MC | Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest … |
| LVTX | LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the … |
| CALTX.ST | Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It … |
| NAMS | NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets … |
| ATAI | Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Pharma Mar
A-Score
1-Year Total Return ->
🥈
Calliditas Therapeutics
A-Score
1-Year Total Return ->
🥉
ProQR Therapeutics
A-Score
1-Year Total Return ->
4
LAVA Therapeutics
A-Score
1-Year Total Return ->
5
NewAmsterdam Pharma
A-Score
1-Year Total Return ->
6
